Bioinformatics for Biobusiness: make biodata work for you

This year EMBL’s European Bioinformatics Institute (EMBL-EBI) is teaming up with Medicines Discovery Catapult (MDC) on 22nd April to deliver an exciting new SME forum: Bioinformatics for Biobusiness (B4BB). This virtual event will promote the power of bioinformatics in driving success across the life science business sectors.

We’re welcoming all businesses engaged in using biodata to take a deep-dive into how to use bioinformatics to grow your business. The agenda has been developed in an open forum style, with a full line-up of expert speakers, including John Overington, Chief Informatics Officer at MDC, Jason Swedlow, Professor of Quantitative Cell Biology at the University of Dundee and Neil Hall, Joint Head of ELIXIR-UK). There is also an opportunity to book a 1:1 meeting with Marc Daigneault, Head of Research Funding at Medicines Discovery Catapult.

Meet in small groups with expert bioinformaticians, and like-minded SMEs using informatics to advance their businesses Explore software tools and services enabling access and analyses in various biomolecular domains Discover available support, and the diverse range of open biological data resources Hear updates on the latest developments in genomics, proteins, chemical biology and imaging Discover available support, and the diverse range of open biological data resources

The half day interactive forum will bring together a raft of information from EMBL-EBI’s bioinformatics resources that are made public and freely available to the global R&D community, and a chance to discover the support available from MDC and their work to reshape the medicines discovery community by championing innovative life science technology in the UK. 

There has been a fantastic response since the event opened for registration, and there are still places available. Visit the website for the full event information including the agenda, register your place and for a chance to view a series of preview videos presented by the experts showcasing resources at B4BB. 

For any other questions contact Effie Mutasa-Gottgens, Senior Scientific Officer or Lucie Smith, Event Organiser, in the EMBL-EBI Industry partnerships team.

       

Follow us:

EMBL-EBI Industry Partnerships: Work with us to solve your data challenges

Partnering with industry has been a core part of EMBL-EBI’s mission right from the very beginning and a significant number of our users come from this sector. As we celebrate an incredible 25 years of industry collaboration next year, let’s hear from Andrew Leach, the new Head of Industry Partnerships at EMBL-EBI to find out a bit more.

Image: Dr Andrew Leach, joined EMBL-EBI in August 2016 following a 20 year career at GSK Research and Development. He took on the role as Head of Industry Partnerships in the summer this year, and will also continue as Head of Chemical Biology.

Industry Partnerships: What does this mean at EMBL-EBI?

Industry Partnerships at EMBL-EBI is about helping to connect public and industry science. We aim to foster and facilitate collaboration, knowledge exchange and networking between scientists and technologists at EMBL-EBI and their counterparts working in industry. We work across multiple sectors and with organisations from very large multinationals to very small start-ups.

Tell us more about the opportunities for scientists in industry to interact with EMBL-EBI.

EMBL-EBI’s Industry Programme is a subscription-based programme for global companies who are using EMBL-EBI’s data and resources as part of their research and development. Representatives from the member companies meet regularly in a forum where we share details of the latest innovations in EMBL-EBI’s services and research. The programme also organises a series of knowledge exchange workshops that explore new emerging areas for R&D. These events are open to any employee of the member companies. The programme also provides a great opportunity for scientists to meet their peers in a pre-competitive, science-oriented environment to discuss the latest developments.

We are always keen to hear of opportunities to explore new strategic partnerships with industry. Open Targets is an excellent example; this ground-breaking public-private consortium was established in 2014 with the overall goal of improving how we identify and prioritise drug targets. Open Targets currently involves six partners: EMBL-EBI, the Wellcome Sanger Institute, GlaxoSmithKline, Bristol Myers Squibb, Takeda and Sanofi.

We also have a proud history of research collaborations that bring together expertise from academia and industry to work on a common research problem or to address a particular data or technology challenge. One particular advantage of collaborating with EMBL-EBI is that we have tremendous flexibility in the way that collaborations can be set up, from small projects lasting a few months, to much larger projects. Key to success is active participation and commitment from everyone involved.

What about smaller companies? 

Every company has to start somewhere and we are committed to engage with small and medium-sized enterprises (SMEs) and start-up enterprises. These are very often the drivers of innovation, and we find that such organisations make extensive use of the resources available at EMBL-EBI. We actively work with organisations such as OneNucleus, the UK Trade and Investment agency (UKTI), the InnovateUK Bioinformatics knowledge-transfer network and the ELIXIR SME and Innovation Forum to showcase the opportunities at EMBL-EBI. Of course, we are also very keen to hear from any smaller company interested in collaborating more directly with us on a particular problem.

What can be achieved by connecting with industry?

Having worked in industry myself (for many years at GSK), I know that industry science is often just as cutting-edge as in traditional academic circles – but historically it has been much less visible due in part to commercial sensitivities together with the fact that publication was not seen as a key goal in industry. These attitudes are changing now; there is a real drive within industry to collaborate externally and especially with leading academic groups and institutions. Industry can bring “real world” applications of the resources and research that we do at the EMBL-EBI; it can be very rewarding to see how the work we do can translate into practical applications. Plus, it can be a way for students and post-docs to get some insights into what a career in industry looks like, and potentially for industry to identify potential recruits for the future!

What would you like to see in the future for Industry Partnerships at EMBL-EBI?

I would like to see our connections with industry continue to grow and strengthen. We have historically had very strong connections with the Pharma and biotech sectors and it would be good to see us strengthen our relationships in other areas of bioscience and also with relevant data science and technology sectors. Of course, we are always keen to create new large-scale strategic partnerships such as Open Targets but we also recognise that a smaller-scale, one-on-one collaboration for example between an SME and an EMBL-EBI Principle Investigator can be equally fruitful. We also want to make further steps to encourage entrepreneurs; this includes working with Jo Mills (Entrepreneurship and Innovation Centre Manager) who with her team is creating a new Startup School for genomics and biodata. This will support early-stage ideas and provide knowledge and confidence to develop them into future products or services.

We always welcome opportunities to explore new partnerships and ventures.

Find out moreGet in touch

Follow us: